Advertisement
Pharma Business – October 3, 2024
AstraZeneca’s supplemental New Drug Application (sNDA) for Calquence has been accepted and granted Priority Review in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL).
Pharma Business – October 2, 2024
AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for Enhertu has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting based on the positive results from the DESTINY-Breast06 Phase III trial which compared Enhertu to chemotherapy.
Financing – October 2, 2024
The Board of Directors of Spago Nanomedical has decided that the company’s resources will be focused on the development of Tumorad with the company’s primary priority being the execution of the ongoing clinical study Tumorad-01 with the candidate drug 177Lu-SN201.
Financing – October 2, 2024
The board of directors of Senzime has resolved on a directed share issue of a maximum of 13 873 000 shares at the subscription price of SEK 6.20 per share.
Financing – October 2, 2024
Vicore Pharma Holding has announced an investment from Sanofi in Vicore through a commitment to subscribe for shares in the ongoing rights issue corresponding to a total of approximately USD 10 million.
Advertisement
Advertisement
Clinical Trials – September 30, 2024
Cereno Scientific has signed an agreement with medical technology company Fluidda on Respiratory Imaging solutions, with the aim to visualize signs of reverse remodeling of lead drug candidate CS1 in Pulmonary Arterial Hypertension (PAH) in a clinical setting.
Clinical Trials – September 19, 2024
Anocca will present its novel platform approach to therapeutic TCR discovery and preclinical data for its lead TCR-T cell therapy product at the European Society of Medical Oncology (ESMO) Congress 2024.
Clinical Trials – September 18, 2024
The results further demonstrate the potential for TILT-123 as an intravenous therapy.
Clinical Trials – September 18, 2024
The company has agreed with the investigators conducting the LUNGVAC trial to discontinue patient recruitment.
Clinical Trials – September 17, 2024
Medivir has presented positive, mature data from its ongoing phase 1b / 2a study of fostroxacitabine bralpamide (fostrox) + Lenvima in advanced liver cancer at the ESMO Congress in Barcelona, Spain.
Clinical Trials – September 14, 2024
Evaxion Biotech has announced new clinical phase 2 data for its lead compound EVX-01.
Pharma Business – October 3, 2024
AstraZeneca’s supplemental New Drug Application (sNDA) for Calquence has been accepted and granted Priority Review in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL).
Pharma Business – October 2, 2024
AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for Enhertu has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting based on the positive results from the DESTINY-Breast06 Phase III trial which compared Enhertu to chemotherapy.
Financing – October 2, 2024
The Board of Directors of Spago Nanomedical has decided that the company’s resources will be focused on the development of Tumorad with the company’s primary priority being the execution of the ongoing clinical study Tumorad-01 with the candidate drug 177Lu-SN201.
Financing – October 2, 2024
The Board of Directors of Spago Nanomedical has decided that the company’s resources will be focused on the development of Tumorad with the company’s primary priority being the execution of the ongoing clinical study Tumorad-01 with the candidate drug 177Lu-SN201.
Financing – October 2, 2024
The board of directors of Senzime has resolved on a directed share issue of a maximum of 13 873 000 shares at the subscription price of SEK 6.20 per share.
MedTech Business – September 20, 2024
For seriously ill children and adolescents, intravenous drip stands can significantly hinder mobility.
Biotech Business – September 27, 2024
Evaxion Biotech has entered into an option and license agreement with MSD for two preclinical vaccine candidates.
Biotech Business – September 24, 2024
The company has received a substantial investment from Kempestiftelserna.
Biotech Business – September 17, 2024
Oncopeptides has announced that it has signed an exclusive license and supply agreement with SCBIO, a Korean pharmaceutical company for the commercialization of Oncopeptides’ flagship drug Pepaxti in South Korea.
Science – July 8, 2024
Unfortunately genes do matter when it comes to obesity, but knowledge about these genes and how they work are key to improving treatment and prevention. “Over the past two decades, genetic association studies have identified hundreds of genetic variations that affect body weight. Individuals who inherit many of these variations are more susceptible to gaining […]
Profiles in Science – June 18, 2024
Anna Falk, Head of Lund University’s Center for Advanced Therapies (LU-ATMP) and principal researcher of the Department of Neuroscience at Karolinska Institutet (KI) shares insights into her research, her multi-faceted job, and her vision for the future of neuroscience. Anna Falk is a molecular biologist with a PhD in neural stem cells and adult neurogenesis. […]
Science – September 20, 2023
An international team of scientists led by the University of Helsinki performed comprehensive mapping of structural alterations in cellular proteins during the aging process. In the study published in Molecular Cell, the team mapped structural alterations in cellular proteins during the aging process and, in the process, identifying new ways aging impacts how cells hum […]
Stryker
Are you ready to drive the market and new product development strategies for a cutting-edge global med tech product?
Stryker
Are you interested in making a difference in healthcare by assisting sales reps and building relationships with customers? As a member of our customer services team, that is exactly what you will do!
Stryker
Stryker’s Trauma division offers market-leading solutions for the treatment of long and small bone fractures. Our portfolio features a comprehensive array of intramedullary nails, external fixation, plating, hand/wrist joint solutions, etc.
Atlas Antibodies
Join Atlas Antibodies and help weave quality and sustainability into every aspect of the company’s business.
Haeger & Carlsson
On behalf of our customer, a Swedish biotech company in a very exciting phase of its development, Haeger&Carlsson recruits the company’s new CFO.
Stryker
As a Territory Sales Manager, you will help us deliver on our mission of making healthcare better by promoting and selling Stryker’s Orthopaedic Instruments products in Göteborg & VGR region of Sweden.
In a new job – September 24, 2024
Urban Eriksson has been appointed as the new Chairman of the board for Umeå Biotech Incubator.
In a new job – August 13, 2024
Margrethe Sørgaard joins the company’s cross-functional R&D team following Calluna’s launch, to oversee the strategic development of the company’s clinical programs in line with regulatory guidelines and safety requirements. With over 25 years’ experience from different leading positions in clinical development and operation, medical affairs, and drug safety/pharmacovigilance, she will play a pivotal role in […]
In a new job – August 6, 2024
Kristina Torfgård has experience in executive management, drug development, regulatory affairs and licensing with major international pharmaceutical companies, including in the field of neurodegenerative diseases. During her time at AstraZeneca, she held senior positions in both early and late-stage R&D and was globally responsible for marketed products. At the biopharmaceutical company Albireo/Pharma, she worked as […]
Careers article – August 12, 2024
Getting back to work after a long and relaxing holiday can be quite hard, here is some advice to make things easier and make your return less stress-free. 1. Plan your return Most people focus on getting organized for departure, perhaps maximizing their time away and then comes home just the day before work begins. […]
Careers article – June 17, 2024
Samuli Ripatti has a background in mathematical statistics but his research has always been focused on applying and developing biostatistical methods to address scientific questions in medical and population genetics. Last year he was appointed Director of the Institute for Molecular Medicine in Finland (FIMM) and NLS asked him about his new role and his […]
Careers article – May 15, 2024
Ulrika Hammarström, CEO and Founder of Scandinavian CRO (SCRO) was recently awarded Entrepreneur of the Year in Uppsala, and NLS asked her about building successful teams, her leadership style and women in life sciences. This prize is awarded by jury to an entrepreneur who has performed above and beyond and whose company has demonstrated long-term […]
Profiles in Business – April 23, 2024
Despite being the co-founder of Ilya Pharma and co-director at the Science for Life Laboratory (SciLifeLab), Dr. Mia Phillipson, considers herself a scientist foremost, not an entrepreneur. “Most of all, I am a scientist. Yes, absolutely. This is my main occupation and the one in which I have the most expertise,” says Mia Phillipson, who […]
Business article – April 17, 2024
Personalized medicine, weight loss remedies and new treatments for widespread ailments are among the rising areas of high interest in the biotechnology and therapeutic arenas, according to executive chairman of Flerie Invest, Thomas Eldered. Thomas Eldered talked with Nordic Life Science about the Nordic and global life science financial landscapes and Flerie’s role in funding […]
Business – November 28, 2023
The previous founder and CEO of BioLamina has gone back to business development, and with his newly founded company he aims to redefine cell therapy development even further. Newly founded Alder Therapeutics is a preclinical phase stem cell therapy development company and, according to Kristian Tryggvason, co-founder and CEO, it is “the next big thing.” […]
This site uses cookies
